Sadighi 2006.

Methods	Single‐centre RCT 2 arms Quality score: D
Participants	n=86 Mean age: 56 years Metastatic disease: 100%
Interventions	ECF: epirubicin 60 mg/m² + cisplatin 60 mg/m² + 5‐FU 750 mg/m²/day as 5 days continuous infusion; repeated at d 22 for 6 cycles TCF: docetaxel 60 mg/m² + cisplatin 60 mg/m² + 5‐FU 750 mg/m² as 5 days continuous infusion; repeated at d 22 for 6 cycles
Outcomes	Response rate Quality of life Overall survival Progression‐free survival
Notes	Extensive analysis of QoL data
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	Unclear risk	Not stated
Incomplete outcome data (attrition bias) efficacy	Unclear risk	No information regarding numbers of patients beside response rates (primary endpoint)
Incomplete outcome data (attrition bias) safety	High risk	For QoL evaluation, only 71 patients were included in the comparative analysis because 15 patients did not complete the QoL measurements at the beginning of the study
Selective reporting (reporting bias)	High risk	Missing information regarding PFS as secondary endpoint
Other bias	Unclear risk	N/A
Blinded review of CT/MRI‐scans?	Unclear risk	Not stated